Biologics may prevent cardiovascular events in rheumatoid arthritis by inhibiting coronary plaque formation and stabilizing high‐risk lesions

Cohort study (n=150) found that current bDMARD use was associated with lower long-term CVD risk (OR 0.15, 95% CI 0.04-0.60). Non-calcified and low attenuation plaque presence moderated this effect on CVD risk.


Arthritis & Rheumatology